Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameYonghe Medical
Stock Code02279
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國領先的專門從事提供毛髮醫療服務的醫療集團,提供一站式毛髮醫療服務,涵蓋植髮醫療、醫療養固、常規養護及其他配套服務。
Listing Date2021-12-13
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京市朝陽區甘露園南里20號中國核建大廈11層
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.yonghegroup.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 15.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 7,900
Par ValueTo be extracted
Offer Period2021-12-01 to 2021-12-06
Global Offering Shares94,424,000 shares
HK Public Offer Shares (Initial)9,443,000 shares (10.0%)
Public Offer Lots (Initial)18,886lots (Pool A9,443lots,Pool B9,443lots)
International Placing Shares (Initial)84,981,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO519,955,916 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share50.0%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,491,899,200

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 7,900
2 lots 1,000 HK$ 15,800
3 lots 1,500 HK$ 23,700
4 lots 2,000 HK$ 31,600
5 lots 2,500 HK$ 39,500
6 lots 3,000 HK$ 47,400
7 lots 3,500 HK$ 55,300
8 lots 4,000 HK$ 63,200
9 lots 4,500 HK$ 71,100
10 lots 5,000 HK$ 79,000
12 lots 6,000 HK$ 94,800
14 lots 7,000 HK$ 110,600
16 lots 8,000 HK$ 126,400
18 lots 9,000 HK$ 142,200
20 lots 10,000 HK$ 158,000
30 lots 15,000 HK$ 237,000
40 lots 20,000 HK$ 316,000
50 lots 25,000 HK$ 395,000
60 lots 30,000 HK$ 474,000
70 lots 35,000 HK$ 553,000
80 lots 40,000 HK$ 632,000
90 lots 45,000 HK$ 711,000
100 lots 50,000 HK$ 790,000
120 lots 60,000 HK$ 948,000
140 lots 70,000 HK$ 1,106,000
160 lots 80,000 HK$ 1,264,000
180 lots 90,000 HK$ 1,422,000
200 lots 100,000 HK$ 1,580,000
400 lots 200,000 HK$ 3,160,000
600 lots 300,000 HK$ 4,740,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
800 lots 400,000 HK$ 6,320,000
1,000 lots 500,000 HK$ 7,900,000
1,200 lots 600,000 HK$ 9,480,000
1,400 lots 700,000 HK$ 11,060,000
1,600 lots 800,000 HK$ 12,640,000
1,800 lots 900,000 HK$ 14,220,000
2,000 lots 1,000,000 HK$ 15,800,000
4,000 lots 2,000,000 HK$ 31,600,000
6,000 lots 3,000,000 HK$ 47,400,000
8,000 lots 4,000,000 HK$ 63,200,000
9,443 lots 4,721,500 HK$ 74,599,700

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.09B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +794%

Valuation & Financials

Market Cap (at Offer Price)HK$ 8,215,303,472
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣163.3百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201820192020
Revenue 934,3261,224,4771,638,297
Cost of sales -232,207-335,379-416,667
Gross profit 702,119889,0981,221,630
Other income and gains, net 9331,4436,304
Selling and distribution expenses -463,681-650,262-779,611
Administrative expenses -93,952-129,962-162,022
Operating profit 128,95898,041266,261
Net finance costs -17,669-26,518-35,347
Profit before tax 111,28971,523230,914
Income tax expense -57,789-35,899-67,582
Profit for the year 53,50035,624163,332
Profit attributable to owners 53,50035,624163,332
Balance Sheet
Item 2018201920202021-06
Cash and cash equivalents 68,47689,789292,856
Trade and bills receivables 9,8055,85910,330
Inventories 14,25514,48626,996
Total current assets 152,647178,433437,612
Total assets 734,445931,2131,594,356
Total current liabilities 205,223280,728505,200
Total liabilities 530,949692,0931,188,298
Total equity 203,496239,120406,058
Equity attributable to owners 203,496239,120406,058
Interest-bearing borrowings 044,82725,870214,395
Cash Flow Statement
Item 2018201920202021-06
Net cash from operating activities 194,567182,480501,571
Net cash from investing activities -102,789-105,352-142,388
Net cash from financing activities -69,689-55,815-156,116
Net increase in cash 22,08921,313203,067
Purchase of PP&E -135,424-105,808-142,204-92,462
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 16.6
First Day OpenHK$ 15.76
First Day Change-85.44%
First Day Volume61374600.0
First Day Turnover1026880000.0
Use of Proceeds
1、約42.1%或571.2百萬港元將用于為我們在中國境內網絡的現有植發醫療機構進行擴充和升級; 2、約17.5%或237.4百萬港元將用于為我們的產品及服務項目創新撥資; 3、約9.7%或131.6百萬港元將用作投資于研發,及以前沿技術提升我們的服務體系; 4、約23.4%或317.5百萬港元將用作在中國整合行業資源以提升我們的品牌知名度; 5、約1.6%或21.7百萬港元將用作結清我們就于2021年5月收購顯赫植發應付關聯方新絲域的并購代價之未償還結余; 6、約5.7%或77.3百萬港元將用作我們的營運資金及一般企業用途。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (2)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Lead Managers (2)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Athos Asia Event Driven Master Fund 38,457,200 HKD — 2.58% — 6 months 2022-06-13
2 Enreal China Master Fund 76,898,600 HKD — 5.15% — 6 months 2022-06-13
3 Hudson Bay Master Fund LTD 76,898,600 HKD — 5.15% — 6 months 2022-06-13
4 Lake Bleu Prime Healthcare Master Fund Limited 76,898,600 HKD — 5.15% — 6 months 2022-06-13
5 LAV Star Limited 76,898,600 HKD — 5.15% — 6 months 2022-06-13
6 NCC China A-Share Master Fund 153,805,100 HKD — 10.31% — 6 months 2022-06-13
7 WT Asset Management Limited 76,898,600 HKD — 5.15% — 6 months 2022-06-13
8 Yi Fang Da Hadar Investment Limited 76,898,600 HKD — 5.15% — 6 months 2022-06-13
9 York Asian Opportunities Investments Master Fund, LP 38,457,200 HKD — 2.58% — 6 months 2022-06-13
10 常春藤资产管理(香港)有限公司 53,838,500 HKD — 3.61% — 6 months 2022-06-13

Directors & Management

PositionChinese nameEnglish Name
Chairman張玉—
Company Secretary韓志梅、梁晶晶—
No director data available.

Major Shareholders

Major Shareholders & Holdings張先生透過ZY Investment Capital Ltd及上海予諾科技控股有限公司持有約34.91%權益;Yonghe Hair Service及CYH共同控制約35.34%權益;ZH Investment Capital Ltd持有約4.62%權益。
About this page

This page shows Yonghe Medical (02279) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect